CY1120103T1 - Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες - Google Patents

Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες

Info

Publication number
CY1120103T1
CY1120103T1 CY20181100358T CY181100358T CY1120103T1 CY 1120103 T1 CY1120103 T1 CY 1120103T1 CY 20181100358 T CY20181100358 T CY 20181100358T CY 181100358 T CY181100358 T CY 181100358T CY 1120103 T1 CY1120103 T1 CY 1120103T1
Authority
CY
Cyprus
Prior art keywords
care
length
pharmaceutical applications
scale system
system compatible
Prior art date
Application number
CY20181100358T
Other languages
English (en)
Inventor
Nicolas Marceau
Mehdi Gasmi
Original Assignee
Genethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48469165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120103(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genethon filed Critical Genethon
Publication of CY1120103T1 publication Critical patent/CY1120103T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά την εκβιομηχάνιση της παραγωγής ανασυνδυασμένων λεντιικών φορέων ώστε να παρασκευαστούν επαρκή υλικά για θεραπευτικές εφαρμογές, όπως η γονιδιακή θεραπεία και/ή ο εμβολιασμός DNA, για χρήση σε κλινικές δοκιμές και/ή εμπορική χρήση.
CY20181100358T 2011-11-24 2018-03-30 Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες CY1120103T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161563566P 2011-11-24 2011-11-24
EP11306551 2011-11-24
EP12795778.5A EP2782997B1 (en) 2011-11-24 2012-11-26 Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
PCT/EP2012/073645 WO2013076309A1 (en) 2011-11-24 2012-11-26 Scalable lentiviral vector production system compatible with industrial pharmaceutical applications

Publications (1)

Publication Number Publication Date
CY1120103T1 true CY1120103T1 (el) 2018-12-12

Family

ID=48469165

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100358T CY1120103T1 (el) 2011-11-24 2018-03-30 Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες

Country Status (19)

Country Link
US (3) US20140315294A1 (el)
EP (2) EP2782997B1 (el)
JP (2) JP6280869B2 (el)
CN (2) CN109097398A (el)
AU (1) AU2012342355B2 (el)
BR (1) BR112014012600A2 (el)
CA (1) CA2856455C (el)
CY (1) CY1120103T1 (el)
DK (1) DK2782997T3 (el)
ES (1) ES2663815T3 (el)
HR (1) HRP20180424T1 (el)
HU (1) HUE036742T2 (el)
LT (1) LT2782997T (el)
PL (1) PL2782997T3 (el)
PT (1) PT2782997T (el)
RS (1) RS57066B1 (el)
SG (1) SG11201402584RA (el)
SI (1) SI2782997T1 (el)
WO (1) WO2013076309A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012342355B2 (en) 2011-11-24 2017-10-12 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
FR3010720B1 (fr) * 2013-09-16 2017-08-11 Genethon Procede de production de virus enveloppes
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
EP3087188A1 (en) * 2013-12-23 2016-11-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
GB201417042D0 (en) * 2014-09-29 2014-11-12 Fkd Therapies Oy Method
PL3294893T3 (pl) 2015-05-13 2024-04-29 Csl Behring Gene Therapy, Inc. Bioprodukcja wektorów lentiwirusowych
CN105483092A (zh) * 2015-10-10 2016-04-13 和元生物技术（上海）股份有限公司 一种中试化生产重组腺相关病毒的新技术
MX2018010061A (es) 2016-02-23 2019-07-04 Immune Design Corp Preparaciones de vectores retrovirales de genomas multiples, y metodos y sistemas para producir y usar las mismas.
KR102535013B1 (ko) * 2016-04-14 2023-05-22 트리젤 엘티디. 정유량 펌프/튜빙 시스템이 있는 고정층 바이오 리액터
CN109890959A (zh) * 2016-09-30 2019-06-14 生命技术公司 慢病毒生产用的无血清悬浮液系统
CN106867877A (zh) * 2017-02-15 2017-06-20 昆明医科大学第二附属医院 一种密闭式慢病毒载体培养装置和培养方法
WO2019086324A1 (en) 2017-10-31 2019-05-09 Ge Healthcare Bio-Sciences Corp. A flexible bag
MA50877A (fr) 2017-11-21 2020-09-30 Bayer Healthcare Llc Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
WO2019123430A1 (en) 2017-12-21 2019-06-27 Casebia Therapeutics Llp Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
CA3084632A1 (en) 2017-12-21 2019-06-27 Crispr Therapeutics Ag Materials and methods for treatment of usher syndrome type 2a
CN110317832B (zh) 2018-03-28 2022-07-05 西比曼生物科技（香港）有限公司 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
CN108866013B (zh) * 2018-08-06 2021-03-23 武汉赛科成科技有限公司 一种大规模生产慢病毒的方法
US20210348192A1 (en) * 2018-09-20 2021-11-11 National University Corporation Tokyo Medical And Dental University Method for increasing lentiviral vector production
CN109401969B (zh) * 2018-12-13 2024-02-02 珠海西格膜生物技术有限公司 一种细胞工厂的管道连接系统及其使用方法
JP7333930B2 (ja) * 2019-01-07 2023-08-28 独立行政法人国立高等専門学校機構 ミミズ細胞の保存方法及びミミズ培養細胞の形質転換方法
CN113122501B (zh) * 2019-12-30 2023-06-16 重庆精准生物技术有限公司 适合大规模临床级病毒载体制备的培养基及其应用
US20230220417A1 (en) * 2020-05-26 2023-07-13 Expression Therapeutics, Llc Lentiviral System
US20240101964A1 (en) * 2020-12-29 2024-03-28 Jiangsu Genscript Probio Biotech Co., Ltd. Hek293t cell strain having high dispersibility and screening method therefor
GB202100688D0 (en) * 2021-01-19 2021-03-03 Autolus Ltd Process
WO2023061409A1 (zh) * 2021-10-12 2023-04-20 江苏金斯瑞蓬勃生物科技有限公司 适应无血清悬浮培养的hek293细胞株及其应用
AU2022371427A1 (en) * 2021-10-19 2024-03-14 Amgen Inc. Composition and methods for recombinant lentiviral production
WO2023200679A1 (en) * 2022-04-11 2023-10-19 Adverum Biotechnologies, Inc. OPTIMIZATION OF HEK293 SUSPENSION PLATFORM FOR IMPROVED rAAV TITERS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722506B1 (fr) 1994-07-13 1996-08-14 Rhone Poulenc Rorer Sa Composition contenant des acides nucleiques, preparation et utilisations
US6210922B1 (en) 1998-11-30 2001-04-03 National Research Council Of Canada Serum free production of recombinant proteins and adenoviral vectors
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
AU2002348151A1 (en) 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
JP5615271B2 (ja) 2008-06-18 2014-10-29 オックスフォード バイオメディカ（ユーケー）リミテッド ウイルス精製法
US20110008894A1 (en) 2009-07-07 2011-01-13 Cayla Lyophilized plasmid/dna transfection reagent carrier complex
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2011097447A2 (en) 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus
EP2661488A1 (en) 2011-01-05 2013-11-13 Expression Therapeutics, LLC Method and system for suspension cell culture
AU2012342355B2 (en) 2011-11-24 2017-10-12 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications

Also Published As

Publication number Publication date
CN104136605B (zh) 2018-08-14
JP6280869B2 (ja) 2018-02-14
CA2856455A1 (en) 2013-05-30
JP2014533516A (ja) 2014-12-15
SG11201402584RA (en) 2014-06-27
EP2782997B1 (en) 2018-01-10
CN104136605A (zh) 2014-11-05
HRP20180424T1 (hr) 2018-06-29
PL2782997T3 (pl) 2018-06-29
US20190211360A1 (en) 2019-07-11
AU2012342355B2 (en) 2017-10-12
BR112014012600A2 (pt) 2017-06-06
RS57066B1 (sr) 2018-06-29
HUE036742T2 (hu) 2018-07-30
LT2782997T (lt) 2018-05-25
US20220235371A1 (en) 2022-07-28
SI2782997T1 (en) 2018-04-30
AU2012342355A1 (en) 2014-07-17
WO2013076309A1 (en) 2013-05-30
EP2782997A1 (en) 2014-10-01
EP3327119A1 (en) 2018-05-30
ES2663815T3 (es) 2018-04-17
DK2782997T3 (en) 2018-04-16
CA2856455C (en) 2022-08-23
US20140315294A1 (en) 2014-10-23
JP2018046828A (ja) 2018-03-29
CN109097398A (zh) 2018-12-28
PT2782997T (pt) 2018-04-09

Similar Documents

Publication Publication Date Title
CY1120103T1 (el) Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1123142T1 (el) Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων
CY1121511T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1120421T1 (el) Ενωσεις και μεθοδοι για διαμορφωση κινασων και ενδειξεις αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1119200T1 (el) Νεα παραγωγα βενζιμιδαζολιου ως ερ4 ανταγωνιστες
CY1120390T1 (el) Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων
MX2017004039A (es) Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso.
CY1117858T1 (el) Ολιγονουκλεοτιδια για την προκληση αλλαγης στην αλληλουχια rna μοριου-στοχου παροντος σε ζωντανο κυτταρο
CR20150258A (es) Anticuerpos anti-ceacam5 y usos de éstos
CY1119055T1 (el) Αντισωματα που προσδενονται στην il-17a και στην il-17f
TR201908550T4 (tr) Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
PH12018500826A1 (en) Extracorporeal life support system and methods of use thereof
CY1116100T1 (el) Παραγωγα πυριμιδινονης, η παρασκευη τους και η φαρμακευτικη τους χρηση
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
BR112014027852A2 (pt) recipientes flexíveis com múltiplos volumes de produto
UY34885A (es) Proteínas de unión anti-mesotelina
MX358706B (es) Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
UY34254A (es) Proteínas y péptidos modificados.
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
EA201492221A1 (ru) Полипептиды, имеющие активность трансгалактозилирования
EA201500172A1 (ru) Модифицированные полипептиды фактора х и их применение
CL2014002846A1 (es) Usos terapéuticos de proteínas del factor de crecimiento del fibroblasto 21.
EA201590359A1 (ru) Лечение ревматоидного артрита